Brief: Kura Oncology Reports First Patient Dosed In Trial Of KO-2806 Plus Cabozantinib In Renal Cell Carcinoma

Kura Oncology

06/03/2024 12:36

March 6 (Reuters) - Kura Oncology Inc  KURA.O :
    * KURA ONCOLOGY REPORTS FIRST PATIENT DOSED IN TRIAL OF
KO-2806
PLUS CABOZANTINIB IN RENAL CELL CARCINOMA
    * KURA ONCOLOGY INC - DOSE ESCALATION OF KO-2806 AS A
MONOTHERAPY
CONTINUES IN PARALLEL
    * KURA ONCOLOGY INC - ANTICIPATES DOSING OF KO-2806 IN
COMBINATION
WITH ADAGRASIB IN KRAS(G12C)-MUTANT NSCLC NEXT QUARTER

Source text for Eikon:  ID:nGNXSV9J1 
Further company coverage:  KURA.O 

 ((Reuters.Briefs@thomsonreuters.com;))